BERN. The National Council has told voters to reject the popular initiative on medical supply security, and to accept a narrower counterproposal from the Federal Council instead. Wednesday’s final vote on the government text passed by 110 to 78, with three abstentions. The Social Democrats, the Greens, the Green Liberals and the Centre carried it. The Swiss People’s Party and the Free Democrats opposed it. The Council of States has not yet spoken. Until it does, neither text is ready for a nationwide vote.

The shortage everyone described

The diagnosis was not in dispute, which is rare in a health debate. From children’s fever syrup to antibiotics and blood pressure drugs, Switzerland has spent recent years rationing medicines that patients expect to find. Five of the six parliamentary groups agreed the initiative, filed in 2024 under the title “Yes to medical supply security”, names a real failure. Lukas Hässig of the Green Liberals, speaking for the majority of the preparatory commission, put the question as the commission sees it: not whether to act, but how to act without writing a blank cheque into the constitution.

Everyone in the chamber agreed the shortages are real. They did not agree to let the initiative write the cure.

The initiative would give the Confederation new powers along the whole medical supply chain, including, as a last resort, the right for the federal government to manufacture medicines itself. The Federal Council accepts the problem and rejects that reach. Its direct counterproposal would tighten cooperation between Bern and the cantons and improve monitoring of which drugs are actually available. It stops short of turning the state into a producer. That last point split even some of the parties that backed the rest of the text.

Rémy Wyssmann of the People’s Party argued that both the initiative and the counterproposal lead to what he called a bureaucratic planned economy in health care. Compulsory stocks of vital medicines already exist, he said, and they work. The state, on his reading of the pandemic, buys either too much or too little and then destroys what it over ordered. FDP councillor Kris Vietze aimed at the manufacturing clause in particular: a power to produce is not only another supply tool, she argued, it puts the Confederation in the role of producer, and that is one competence too many.

Why the counterproposal won the chamber

The People’s Party tried to stop the debate on the counterproposal before it began. The Council refused, by 134 to 52, with two abstentions. The subsequent line up was the health argument in miniature. The left and the centre wanted a constitutional hook and a federal duty to watch the shelves. The right wanted fewer rules for the industry that already makes a large share of the world’s medicines a short train ride from Basel, not a new federal factory. Parliament chose the middle text and recommended a No to the initiative.

The practical stakes sit in pharmacies, not in the chamber. A monitoring duty does not, by itself, put amoxicillin back on a shelf in January. What it can do is force earlier warning when a supplier fails, and give Bern and the cantons a shared list of what is missing. The industry’s answer remains the one it has given for a decade: price pressure in the basic insurance list makes low margin generics unattractive to keep in stock. Neither Wednesday’s text nor the initiative settles that price fight. Both assume that information and coordination will do some of the work that margins do not.

Households will meet a more immediate health number first. On 29 September, health minister Elisabeth Baume-Schneider is due to announce the average 2027 premium, a rise whose size is still a forecast. Medicine shortages and premium letters are the same system seen from two ends: one is a missing box, the other is the bill for a system that keeps adding treatments faster than wages rise. Parliament is in session with both on the table.

The Council of States now inherits two documents and a recommendation. It can echo the National Council, harden the counterproposal, or revive the argument about a federal power to manufacture. Voters will not see a ballot until both chambers agree on what, exactly, they are being asked to put in the constitution. Wednesday settled the lower house. It did not settle the shortage.